Skip to main content
. 2023 Sep 7;10:1261330. doi: 10.3389/fcvm.2023.1261330

Figure 5.

Figure 5

Induction of NIS-expressing human pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). (A) Immunostaining of NIS in NIS-expressing and NIS non-expressing human iPSC-CMs at differentiation day 31. Scale bars are 400 µm. (B) Immunostaining of NKX2-5, a marker of working cardiomyocytes, and cardiac troponin T (cTnT) in NIS-expressing and NIS non-expressing human iPSC-CMs at differentiation day 31. Scale bars are 200 µm. (C) Immunostaining of α-actinin and Connexin 43 in NIS-expressing and NIS non-expressing human iPSC-CMs. Scale bars are 100 µm. (D) Immunostaining of α-actinin and MLC2v, a marker of ventricular cardiomyocytes, on differentiation day 50 in NIS-expressing and NIS non-expressing human iPSC-CMs. Scale bars are 100 µm. (E) Uptake of 125I of human iPSC-CMs at differentiation day 35 in vitro. NaClO4 is an inhibitor of NIS. Data are shown as mean ± standard deviation (n = 5 in each). *p < 0.001 vs. NIS (+) w/o 200 µM NaClO4 (ANOVA/Bonferroni). (F) NIS-expressing human iPSC-CMs were cultured for 10 days from differentiation day 21, and cell viability was evaluated using CCK-8 assay. Data are shown as mean ± standard deviation (n = 6 in each, ANOVA/Bonferroni).